Login to Your Account



Pharma: Other News To Note


Thursday, July 25, 2013

• Merck & Co. Inc., of Whitehouse Station, N.J., said the FDA has accepted for standard review its new drug application for its investigational anti-thrombotic medicine, vorapaxar for the secondary prevention of cardiovascular events in patients with a history of heart attack and no history of stroke or transient ischemic attack.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription